Bioelectronics Corp (BIEL)

[JNdouble1]

What is different this time?

Actipatch has been available in most of those countries for a decade or more.

This is RecoveryRX, so BIEL has to do the marketing themselves, no value added resellers to do the branding and advertising for them.

Biel has no capital for advertising, how do you see the product gaining recognition when it never did previously?

The prescription pathway didn't work in the UK, OTC has been a global failure for actipatch, so again, what is different this time?

Approval by US regulators doesn't mean that much in many of the countries listed. In many of them the product was already approved.